1. Executive Summary
1.1 Summary Points
1.2 Aims, Scope and Format of this Report
1.2.1 Speculative Aspects of Assessing the Biobanking Market
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods
2. Introduction to Biobanking
2.1 Biobanking
2.1.1 Processes Involved in Biobanking
2.2 Biobanks: A Two-fold Character
2.3 Key Features
2.4 Classification of Biobanks
2.4.1 Volunteer Groups
2.4.1.1 Population-based Biobanks
2.4.1.2 Disease-oriented Biobanks
2.4.2 Ownership or Funding Structure
2.5 Guidelines and Standards
2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research
2.5.2 Industry Standards for Biobanks
2.5.3 Biobanking Processes Governed by Guidelines
2.6 Laws and Regulations for Biobank-based Research
3. Biobanking and the Pharmaceutical Industry
3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry
3.1.1 Research and Drug Development
3.1.1.1 Understanding Disease Pathways
3.1.1.2 Drug Discovery
3.1.1.3 Biomarker Discovery
3.1.2 Therapeutics
3.1.3 Clinical Trials
3.2 Biobanks Operated by Pharmaceutical Companies
4. Biobanking: Associated Market (Systems, Software, Consumables, and Services Associated with Biobanking)
4.1 Systems/ Technologies
4.1.1 Automated Liquid Handling
4.1.1.1 Frozen Aliquotting: New Technology in Development
4.1.2 Storage
4.1.2.1 Ultra-low Temperature Freezing
4.1.2.2 Room-Temperature Storage
4.1.3 RFID and Tagging Technologies
4.2 Software
4.2.1 Laboratory Information Management System (LIMS)
4.2.1.1 LIMS Functions
4.3 Consumables
4.4 Services
5. Global Biobanking Market, 2010-2025
5.1 Current State of the Biobanking Market
5.2 Geographical Footprint
5.3 Growing Demand for Biobank Resources
5.4 Revenue Forecast for Total Biobanking Market
5.4.1 Scope and Limitations
5.4.2 Biobanking Market, 2010-2025
5.5 Commercial Biobanks: New Resources for Research
6. Human Tissue Banking Market
6.1 Revenue Forecast for Total Human Tissue Banking Market, 2010-2025
6.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank, 2010-2025
6.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets, 2010-2025
6.4 Commercial Participants in the Human Tissue Banking Market
6.4.1 Business Models of Companies in the Biobanking Market
6.4.2 Tissue Solutions Ltd.
6.4.2.1 Overview
6.4.2.2 Global Presence
6.4.2.3 Products and Services
6.4.2.3.1 Banked Samples
6.4.2.3.2 Prospective Samples
6.4.2.3.3 Fresh Samples
6.4.2.3.4 Freshly Isolated and Primary Cells
6.4.2.3.5 Services
6.4.2.4 Strengths and Capabilities
6.4.2.5 Future Outlook
6.4.3 Asterand Plc.
6.4.3.1 Overview
6.4.3.2 Global Presence
6.4.3.3 Products and Services
6.4.3.3.1 XpressBANK
6.4.3.3.2 ProCURE
6.4.3.3.3 PhaseZERO
6.4.3.3.4 BioMAP
6.4.3.4 Asterand: Providing Barriers for New Market Entrants?
6.4.3.5 Financial Performance
6.4.3.6 Future Outlook
7. Stem Cell Banking
7.1 Overview
7.2 Revenue Forecast for Total Stem Cell Banking, 2010-2025
7.3 Stem Cell Banks for Research: High Growth Possible
7.4 Umbilical Cord Blood Banking for Stem Cells
7.4.1 Biological Insurance: Private Blood Banking
7.4.2 Umbilical Cord Banking: The Controversies
7.4.2.1 US Oversight of Cord Blood Stem Cells
7.4.3 Companies in the Field
7.4.3.1 Cord Blood America: Looking Towards the Chinese Market
7.4.3.2 ViaCord: 145,000 Blood Units in Storage
7.4.3.3 Cryo-Cell International: The First Cord Blood Bank
7.4.3.4 Stem Cell Authority: Exclusive Stem Cells
7.4.3.5 LifebankUSA: Placenta-Cord Banking
7.5 Gene/ DNA Banking
8. Industry Trends
8.1 Automated Biobanking
8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in Biobanking
8.1.2 Addressing Sample Storage and Tracking Issues
8.2 Green Banking
8.3 Creation of National Biobanks
8.4 HIPAA Amendments
9. SWOT Analysis of the Biobanking Sector
9.1 Strengths
9.1.1 Wealth of Information for Genetic Research
9.1.2 Potential to Change Treatments
9.1.3 Many Governments Support Biobanking
9.2 Weaknesses
9.2.1 Quality Concerns for Existing Biospecimen Collections
9.2.2 Lack of Standardisation and Harmonisation of Best Practices
9.2.3 Limited Sharing and Linkage of Biobanks
9.3 Opportunities
9.3.1 Genome-Wide Association Studies (GWAS)
9.3.2 Personalised Medicine
9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach
9.4 Threats
9.4.1 Ethical and Regulatory Issues
9.4.1.1 Limitations of Informed Consent in Biobanking
9.4.1.2 Confidentiality and Security to Prevent Improper Use
9.4.2 Social and Cultural Issues
9.4.3 Ownership Issues
9.4.4 Funding
10. Expert Opinion
10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions
10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry
10.1.2 On Commercial Aspects of Biobanking
10.1.3 On the Business of Tissue Solutions
10.1.4 On the Attractiveness of Human Tissue Banking
10.1.5 On the Future of the Biobanking Market
11. Conclusions
11.1 Biobanking for Research and Therapeutics
11.2 Biobanking: The Future for Drug Discovery and Personalised Medicine?
11.3 Commercial Drivers of the Biobanking Market
11.4 The Sector Has Marked Challenges, but Many Opportunities for Growth
[Inhaltsverzeichnis ausblenden]
